3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Neoplasms
14
Venous Thromboembolism
11
Venous Thrombosis
4
Thrombosis
3
Pulmonary Embolism
3
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Interventions
pembrolizumab
3
atezolizumab
2
Sugammadex
2
Saline Solution
2
Paclitaxel
2
Neostigmine
2
Gemcitabine
2
Cetuximab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
poly ICLC
1
lenvatinib
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
delta 24-sterol reductase
1
daratumumab
1
cabozantinib
1
abemaciclib
1
Zoledronic Acid
1
Water
1
Valproic Acid
1
Urinary Diversion
1
Ultrasonography
1
Trastuzumab
1
Tomography, Optical Coherence
1
Tissue Banks
1
Therapeutics
1
Testosterone Propionate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urologic Neoplasms
×
Rivaroxaban
×
Clear all
NCT05920343
2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3
Recruiting
120 enrolled